7,428.00

+26.00

+0.35%

51,716.00

+331.00

+0.64%

27,128.50

+43.25

+0.16%

Russell 2000 Futures

2,789.40

+28.90

+1.05%

4.8590

+0.0220

+0.45%

23.96

-1.68

-6.54%

4,106.00

+31.10

+0.76%

74,130.78

-1,655.65

-2.18%

Crude Oil Dec 26

90.33

-0.50

-0.55%

US Private Equity

10,772.76

+11.83

+0.11%

Toronto - Delayed Quote CAD

Eupraxia Pharmaceuticals Inc. (EPRX.TO)

9.71 +0.48 (+5.20%)

At close: November 6 at 4:00:00 PM EST

Loading Chart for EPRX.TO

Chart Range Bar

Interval:

In partnership with ChartIQ

Eupraxia Pharmaceuticals Announces Voting Results from Annual General Meeting of Shareholders

Eupraxia Pharmaceuticals Announces Voting Results from Annual General Meeting of Shareholders

Eupraxia Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference

Eupraxia Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference

Eupraxia Pharmaceuticals Q1 Loss Narrows

Eupraxia Pharmaceuticals Q1 Loss Narrows

Eupraxia Pharmaceuticals’ First Release of EoEHSS Sub Scores Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week

Eupraxia Pharmaceuticals’ First Release of EoEHSS Sub Scores Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week

Eupraxia Pharmaceuticals Reports EREFS Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week (DDW)

Eupraxia Pharmaceuticals Reports EREFS Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week (DDW)

Eupraxia Pharmaceuticals Appoints Dr. Jeymi Tambiah as Chief Medical Officer

Eupraxia Pharmaceuticals Appoints Dr. Jeymi Tambiah as Chief Medical Officer

Eupraxia Pharmaceuticals to Present at Digestive Disease Week Annual Meeting

Eupraxia Pharmaceuticals to Present at Digestive Disease Week Annual Meeting

Eupraxia Reports Latest 36-Week Results From Resolve Trial

Eupraxia Reports Latest 36-Week Results From Resolve Trial

Eupraxia Pharmaceuticals Reports Positive Nine-Month Tissue Health and Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis

Eupraxia Pharmaceuticals Reports Positive Nine-Month Tissue Health and Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis

Eupraxia Pharmaceuticals to Present at Upcoming Investor Conferences

Eupraxia Pharmaceuticals to Present at Upcoming Investor Conferences

Eupraxia Pharmaceuticals Closes US$63.2M Public Offering Including Full Exercise of Underwriter Option

Eupraxia Pharmaceuticals Closes US$63.2M Public Offering Including Full Exercise of Underwriter Option

Mobilize your Website

View Site in Mobile | Classic

Share by: